| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis.
|
J Thromb Haemost
|
2009
|
4.30
|
|
2
|
Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction.
|
J Am Coll Cardiol
|
1998
|
3.16
|
|
3
|
Platelet functions beyond hemostasis.
|
J Thromb Haemost
|
2009
|
2.23
|
|
4
|
The accumulation and elimination of crude and clarified poliovirus suxpensions by shellfish.
|
Am J Epidemiol
|
1969
|
2.10
|
|
5
|
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.
|
J Am Coll Cardiol
|
1998
|
1.95
|
|
6
|
Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases.
|
Am J Surg Pathol
|
1999
|
1.82
|
|
7
|
Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction.
|
J Am Coll Cardiol
|
1997
|
1.49
|
|
8
|
Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective.
|
Am Heart J
|
1990
|
1.48
|
|
9
|
Viscous Rayleigh-Taylor instability experiments at high pressure and strain rate.
|
Phys Rev Lett
|
2010
|
1.45
|
|
10
|
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
|
J Thromb Haemost
|
2005
|
1.42
|
|
11
|
Mechanical failure of a St. Jude Medical prosthesis.
|
Am J Cardiol
|
1991
|
1.39
|
|
12
|
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
|
J Thromb Haemost
|
2008
|
1.13
|
|
13
|
Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.
|
Oligonucleotides
|
2007
|
1.12
|
|
14
|
Ischemic preconditioning may be transferable via whole blood transfusion: preliminary evidence.
|
J Thromb Thrombolysis
|
1999
|
1.05
|
|
15
|
Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2]).
|
Am J Cardiol
|
2001
|
1.00
|
|
16
|
Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease.
|
Dig Dis Sci
|
1985
|
0.96
|
|
17
|
Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarction.
|
Am J Cardiol
|
1996
|
0.94
|
|
18
|
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
|
J Clin Pharmacol
|
2014
|
0.91
|
|
19
|
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.
|
Am J Cardiol
|
1998
|
0.88
|
|
20
|
Primary tumors of the heart: a review with emphasis on diagnosis and potential treatment modalities.
|
Semin Surg Oncol
|
1985
|
0.87
|
|
21
|
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
|
J Am Coll Cardiol
|
1994
|
0.86
|
|
22
|
Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.
|
J Thromb Thrombolysis
|
2011
|
0.85
|
|
23
|
The cleaved peptide of the thrombin receptor is a strong platelet agonist.
|
Proc Natl Acad Sci U S A
|
1998
|
0.85
|
|
24
|
Massive hemolysis in Clostridium perfringens infections.
|
J Surg Oncol
|
1987
|
0.82
|
|
25
|
A comparison of heparin strategies after thrombolytic therapy.
|
Am Heart J
|
1993
|
0.82
|
|
26
|
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
|
Am Heart J
|
2001
|
0.81
|
|
27
|
Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
|
Curr Pharm Biotechnol
|
2012
|
0.80
|
|
28
|
A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent.
|
J Thromb Haemost
|
2012
|
0.79
|
|
29
|
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).
|
Thromb Haemost
|
2011
|
0.78
|
|
30
|
Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council.
|
Clin Cardiol
|
1999
|
0.77
|
|
31
|
Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock.
|
Am Heart J
|
1993
|
0.77
|
|
32
|
Adjuvant antiplatelet strategies in coronary thrombolysis.
|
Circulation
|
1991
|
0.76
|
|
33
|
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
|
J Thromb Haemost
|
2004
|
0.76
|
|
34
|
Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.
|
Am J Cardiol
|
1996
|
0.76
|
|
35
|
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
|
J Thromb Thrombolysis
|
2000
|
0.76
|
|
36
|
Primary prevention of coronary heart disease in women.
|
Cardiology
|
1995
|
0.76
|
|
37
|
Myocardial infarction in patients undergoing noncardiac surgery.
|
Cleve Clin J Med
|
1987
|
0.75
|
|
38
|
Coronary heart disease risk factors in women.
|
Cardiology
|
1990
|
0.75
|
|
39
|
Pulmonary embolism: a review of 200 cases with emphasis on pathophysiology, diagnosis, and treatment.
|
Cleve Clin Q
|
1984
|
0.75
|
|
40
|
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
|
J Thromb Thrombolysis
|
2001
|
0.75
|
|
41
|
Beta-adrenergic blockade in the thrombolytic era.
|
Cardiology
|
1992
|
0.75
|
|
42
|
Tissue plasminogen activator and intracranial hemorrhage.
|
Ann Intern Med
|
1990
|
0.75
|
|
43
|
Incidence of stroke may be on the rise.
|
Stroke
|
1997
|
0.75
|
|
44
|
Adaptive and maladaptive cardiovascular responses in human sepsis.
|
Am Heart J
|
1991
|
0.75
|
|
45
|
Cardiogenic shock: elements of etiology, diagnosis, and therapy.
|
Clin Cardiol
|
1993
|
0.75
|
|
46
|
Marine omega-3 fatty acids and atherosclerosis.
|
Ann Intern Med
|
1988
|
0.75
|
|
47
|
Circadian variations in cardiovascular disease.
|
Cleve Clin J Med
|
1989
|
0.75
|
|
48
|
Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors.
|
Am Heart J
|
1994
|
0.75
|
|
49
|
Diagnosis and management of inherited and acquired thrombophilias.
|
J Thromb Thrombolysis
|
1999
|
0.75
|
|
50
|
Novel inhibitors of factor X for use in cardiovascular diseases.
|
Curr Cardiol Rep
|
2000
|
0.75
|
|
51
|
Cardiovascular disease in patients with chronic renal failure.
|
Cleve Clin J Med
|
1989
|
0.75
|
|
52
|
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
|
Am Heart J
|
1998
|
0.75
|
|
53
|
Management of post-infarction angina.
|
Cardiol Clin
|
1988
|
0.75
|
|
54
|
Variant angina pectoris. Is the parasympathetic nervous system at fault?
|
Chest
|
1987
|
0.75
|
|
55
|
Calcium channel antagonists in the modern era of coronary thrombolysis: benefit or detriment?
|
Cardiovasc Drugs Ther
|
1996
|
0.75
|
|
56
|
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
|
J Thromb Thrombolysis
|
2000
|
0.75
|
|
57
|
Acquired factor X deficiency in systemic amyloidosis.
|
Cleve Clin J Med
|
1987
|
0.75
|
|
58
|
Nocturnal diaphoresis and coronary artery spasm. Contribution of the parasympathetic nervous system.
|
Cleve Clin J Med
|
1988
|
0.75
|
|
59
|
Noninvasive diagnosis of coronary heart disease in women.
|
Cardiology
|
1990
|
0.75
|
|
60
|
Effect of serum total cholesterol on hemorrhagic complications following thrombolytic therapy for acute myocardial infarction.
|
Cardiology
|
1991
|
0.75
|
|
61
|
Anticardiolipin antibodies in patients with unstable angina.
|
Cardiology
|
1994
|
0.75
|
|
62
|
Penicillamine-induced insulin antibodies.
|
Ann Intern Med
|
1986
|
0.75
|
|
63
|
Right-sided endocardial lesions and flow-directed pulmonary artery catheters.
|
Cleve Clin J Med
|
1987
|
0.75
|
|
64
|
Cardiogenic shock complicating coronary artery disease: diagnosis, treatment, and management.
|
Curr Probl Cardiol
|
1994
|
0.75
|
|
65
|
The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.
|
J Thromb Thrombolysis
|
2014
|
0.75
|
|
66
|
Nocturnal diaphoresis in Prinzmetal angina.
|
Ann Intern Med
|
1987
|
0.75
|
|
67
|
Thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus.
|
Cleve Clin Q
|
1985
|
0.75
|
|
68
|
Rapid resolution of acute cor pulmonale with recombinant tissue plasminogen activator.
|
Chest
|
1989
|
0.75
|
|
69
|
Mechanisms and management of cardiogenic shock.
|
Crit Care Clin
|
1993
|
0.75
|
|
70
|
Cardiac rhabdomyosarcoma: case report with review of clinical and pathologic features.
|
Cleve Clin Q
|
1984
|
0.75
|